| scholarly article | Q13442814 |
| P50 | author | Jaakko Tuomilehto | Q28050079 |
| Franciszek Kokot | Q3303356 | ||
| Philippe Amouyel | Q30435924 | ||
| Michel Marre | Q37631006 | ||
| Lionel Opie | Q61046058 | ||
| Bryan Williams | Q90687501 | ||
| P2093 | author name string | Constantin Ionescu-Tirgoviste | |
| Kjeld Hermansen | |||
| Roland Asmar | |||
| André Scheen | |||
| Decio Mion Júnior | |||
| Margarita Fernandez | |||
| Yves Gallois | |||
| Juan Garcia Puig | |||
| György Jermendy | |||
| Jean-Pierre Ollivier | |||
| M Helena Saldanha | |||
| Aaron Halabe | |||
| Bartolomé Finizola | |||
| Maximino Ruiz | |||
| Valentin Moyseev | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enalapril | Q422185 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1613-1622 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Journal of Hypertension | Q6295318 |
| P1476 | title | Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study | |
| P478 | volume | 22 |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q34668757 | A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial |
| Q36324886 | An overview of the pharmacology and clinical efficacy of indapamide sustained release |
| Q53330039 | Blood pressure management in patients with type 2 diabetes mellitus. |
| Q26766599 | Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials |
| Q84130177 | Diabetes: Renal benefits of lowering BP in the absence of hypertension |
| Q36783880 | Diuretic treatment of hypertension. |
| Q38180204 | Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics |
| Q36609875 | Diuretics: a modern day treatment option? |
| Q37051470 | Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? |
| Q43143752 | Effects of additional administration of low-dose indapamide on patients with hypertension treated with angiotensin II receptor blocker. |
| Q45385807 | Efficacy and Acceptability of Indapamide Sustained Release in Elderly High-Risk Hypertensive Patients : the ARGUS Study. |
| Q35980999 | Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure |
| Q36384453 | Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. |
| Q38373862 | Evidence-based diuretics: focus on chlorthalidone and indapamide |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q93336584 | First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension |
| Q88524965 | First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus |
| Q91362509 | Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension |
| Q37886063 | Identification and management of albuminuria in the primary care setting |
| Q36383782 | Indapamide sustained release: a review of its use in the treatment of hypertension |
| Q30353386 | Management of Diabetic Nephropathy in the Elderly: Special Considerations. |
| Q37566053 | Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians |
| Q36216253 | New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics |
| Q87016442 | Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension |
| Q38020945 | Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy |
| Q34979484 | Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis |
| Q92437336 | Redefining diuretics use in hypertension: why select a thiazide-like diuretic? |
| Q36362572 | Renal protection in hypertensive patients: selection of antihypertensive therapy |
| Q37970579 | Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis |
| Q34434606 | Safety of ACE inhibitor therapies in patients with chronic kidney disease |
| Q92377672 | The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) |
| Q92861385 | The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: a systematic review and meta-analysis of randomized controlled trials |
| Q37788947 | The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor |
| Q27007027 | Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. |
| Q90212013 | Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials |
| Q38243976 | Thiazide-like/calcium channel blocker agents: a major combination for hypertension management |
| Q51013998 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. |
| Q37104853 | Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan |
| Q49331449 | Type 2 Diabetes and Thiazide Diuretics |
Search more.